drugset
drugset / Trial / NCT05440799

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

NCT05440799 ↗

Phase 1 Completed 62 enrolled Boehringer Ingelheim
RandomizedSequentialQuadruple-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy female subjects of non-childbearing potential.

Timeline

Start
2022-07-20
Primary completion
2023-08-02
Completion
2023-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1819479 Unknown — —

Indications

No indication recorded.